Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.
about
Molecular pathology of prostate cancerProstate cancer metastasis: roles of recruitment and reprogramming, cell signal network and three-dimensional growth characteristicsMet in urological cancersReceptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancersNormal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factorProstate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting.Met-Independent Hepatocyte Growth Factor-mediated regulation of cell adhesion in human prostate cancer cells.Plexin-B1 mutations in prostate cancer.Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells.Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607.Efficacy of c-Met inhibitor for advanced prostate cancer.Hepatocyte growth factor/scatter factor-induced intracellular signalling.Correlation of Epstein-Barr virus and its encoded proteins with Helicobacter pylori and expression of c-met and c-myc in gastric carcinomaCabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasisActivation of c-MET induces a stem-like phenotype in human prostate cancerMechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression.Future directions in the field of endometrial cancer research: the need to investigate the tumor microenvironment.The Met oncogene and basal-like breast cancer: another culprit to watch out for?A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings.RasGRP3 contributes to formation and maintenance of the prostate cancer phenotype.Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer.Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progressionExpression of the c-Met Proteins in Malignant Skin CancersPhenotypic switch from paracrine to autocrine role of hepatocyte growth factor in an androgen-independent human prostatic carcinoma cell line, CWR22R.MET and VEGF: synergistic targets in castration-resistant prostate cancerThe PCa Tumor Microenvironment.Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular proteinExpression of Met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors.Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptorHepatocyte growth factor secreted by prostate-derived stromal cells stimulates growth of androgen-independent human prostatic carcinoma cells.Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer.Expression of SOCS1 and the downstream targets of its putative tumor suppressor functions in prostate cancer.Humanized anti-hepatocyte growth factor (HGF) antibody suppresses innate irinotecan (CPT-11) resistance induced by fibroblast-derived HGF.Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer.Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer.Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancerA dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.Ligand-independent activation of MET through IGF-1/IGF-1R signaling.From AR to c-Met: androgen deprivation leads to a signaling pathway switch in prostate cancer cells.
P2860
Q24672410-6BCC921C-9667-47E9-AA29-D95C92A79F0AQ26773613-9C117C68-FE70-4938-8AB3-B9EA1DA36145Q26864988-A06F240A-B4C0-4A6A-A81D-26977B9CA4A3Q28082793-D1FAE658-3E74-4F31-AC12-9E113FBE2AF2Q28345285-89691F50-8869-4AEE-816E-1E193C90FEF7Q30409623-FD549CD6-5D7B-48A2-B8C7-2E2C5B6A3E74Q30446159-F2CBED32-27F6-49E8-BF32-70084265CC37Q30480866-3917CF3D-50BF-4134-A1ED-43D176CB2AA2Q30501331-A0CECFC2-2817-436D-B775-F660928050EAQ31062741-DF28CBA4-8486-469F-8B3C-1EA79A895FC0Q33718726-946FEAFB-B952-4558-93C8-E510EF6637DEQ33863966-278E37DB-BDDE-4C19-ACCC-55EAA6600A58Q33866559-F28552B6-CD7D-4331-ADB7-D60D448AC112Q33946929-F5A00E8C-21AB-41C9-9595-BFA6DB7A17A2Q33947318-FA783814-45EA-4A24-A5C3-3B0A57F562A6Q34081431-365D4E02-56BC-48B9-8369-8F5B911D019EQ34085432-5D998477-701E-4492-BA80-2EF9B8DF843DQ34105580-8B60DA85-0891-4EEE-9A3E-B1551EF55825Q34173500-1C128E7E-F6FF-4230-954E-0F22D46857DAQ34185858-BE3F3677-4B7C-4C57-B7F6-140F1EC3584DQ34203989-C90A51E5-620E-4AD5-9363-1CBF8472EA2CQ34309227-5E959C8C-18A5-4D34-A58D-05CADAA090C0Q34394070-5077B2A7-0B6F-4B37-8FFF-238C532AE9A9Q35059638-8DD6F2A6-F2D9-40DE-825D-D3149B0243E3Q35102980-5D3B62B3-1084-4370-B806-B6E22E3964A7Q35575488-C7A48F0A-D1A5-403E-953C-72F17AE6DD2DQ35603143-307C0F6B-4129-44C2-BC07-FCB6191BFE42Q35747784-7DF7A5DF-01B2-4471-BF11-64FAF7D2BA2BQ35782214-7D80CD9E-1AC0-4409-836E-E03A31687338Q35788293-6E1E69E1-53CF-40AB-BBEF-08C1A3FB6383Q35829375-31583858-772A-4538-85E9-26769CD96D3AQ36051783-996E140A-514D-40B1-BF3B-6A88618A4C49Q36290408-FCFE0C71-7A3F-4040-8C24-CDE68CA89AB4Q36414376-E9E35107-200F-4AD8-A320-5F938D1CA96AQ36527826-4FD1A561-155F-4DEF-B77B-2A50278D32A4Q36840731-C8CC16D1-7AA6-43F3-AE7F-4D6F70BF36B4Q36931715-D05D195C-27C2-46E3-99DA-00D08BEFDE4FQ36934749-37C94443-E9D1-43AE-8E73-F614DB2A584AQ37018397-D6BFA768-A6F7-4423-8896-9351A6D2855AQ37313321-865C9B4A-FC1F-4292-8340-3F68D09ECA28
P2860
Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.
@ast
Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.
@en
type
label
Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.
@ast
Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.
@en
prefLabel
Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.
@ast
Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.
@en
P2093
P2860
P1476
Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma
@en
P2093
P A Humphrey
P E Swanson
R T Vollmer
R Zarnegar
T L Ratliff
P2860
P304
P407
P577
1995-08-01T00:00:00Z